Abstract
ABSTRACTObjectives:There is a cross-link of insulin and insulin-like growth factor-1 (IGF-1) with each other’s receptors. The present study was carried out to explore the relationship of Type-2 diabetes mellitus (T2DM) with the occurrence and development of breast cancer by analyzing the expression of IGF-1R and Ki-67, as well as the biological characteristics in breast cancer patients with and without diabetes mellitus.Methods:A total of 102 cases of breast cancer patients with T2DM admitted in Hebei General Hospital from January 2019 to December 2020 were selected and grouped in T2DM group. While the control group included 106 cases of breast cancer patients without diabetes mellitus in the same period. Further comparison was conducted focusing on the general data, clinical stage, tumor histological grade, molecular classification and prognosis, and the expressions of IGF-1R and Ki-67 in breast cancer tissue between groups.Results:Compared with control group, patients in T2DM group were elderly and accounted for a larger proportion of post-menopause (p<0.05), yet with no significant difference in body mass and family history (p>0.05). Compared with control group, T2DM group had advanced clinical stage, higher histological grade, and more common molecular type, with statistical differences between groups (p<0.05). Furthermore, there were higher proportions of local recurrence, lymph node metastasis and distant metastasis in T2DM group than those in control group, yet with no statistical significance (p>0.05). While statistical difference was found in the comparison of the 5-year survival rate, which was lower in T2DM group than that in control group (p<0.05). In addition, compared with control group, there were significant increase in both the expressions of IGF-1R and Ki-67 in T2DM group (p<0.05).Conclusions:T2DM may be one of the risk factors affecting the occurrence, development and prognosis of breast cancer, which may decrease the 5-year survival of breast cancer patients. Besides, high expressions of IGF-1R and Ki-67 may be the key factors for poor prognosis of breast cancer patients with diabetes mellitus.
Highlights
Breast cancer ranks the first in female malignant tumors, which seriously endangers women’s life and health.[1,2] Simultaneously, Type-2 diabetes mellitus (T2DM) has become a major global public health problem
The purpose of our study was to explore the effect of T2DM on the biological characteristics of breast cancer, and to investigate whether the difference of Insulin-like growth factor-1 receptor (IGF-1R) and Ki-67 expressions in breast cancer affects the prognosis of these patients with diabetes mellitus
There was no significant difference in body mass and family history between T2DM group and control group (p>0.05)
Summary
Breast cancer ranks the first (about 28%) in female malignant tumors, which seriously endangers women’s life and health.[1,2] Simultaneously, Type-2 diabetes mellitus (T2DM) has become a major global public health problem. Insulin-like growth factor-1 receptor (IGF-1R), a transmembrane tyrosine protein receptor, is highly expressed in nervous system malignancies, hepatocellular carcinoma, breast cancer, adrenocortical tumors and lung cancer. It plays an important role in cell proliferation, differentiation and apoptosis by binding with its ligands. Ki-67 protein is a tumor proliferation antigen that is related to cell cycle It can effectively evaluate the proliferative activity of tumor cells,[6] which is associated with the occurrence, development and prognosis of various tumors. The purpose of our study was to explore the effect of T2DM on the biological characteristics of breast cancer, and to investigate whether the difference of IGF-1R and Ki-67 expressions in breast cancer affects the prognosis of these patients with diabetes mellitus. It is expected to provide experimental and theoretical basis for evaluating the relationship of diabetes mellitus with the occurrence and development of breast cancer, which is of great significance for the prevention and treatment of breast cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
